rawf8 / Shutterstock.com
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
The price of patented medicines in Canada is regulated by the Patented Medicine Prices Review Board (PMPRB), an independent, quasi-judicial body established under the Patent Act to ensure the prices of patented medicines are not excessive.
The PMPRB exercises its regulatory mandate by monitoring the factory gate price of patented medicines and ordering remedies when the price is determined to be excessive. It has jurisdiction only on patentees and has no regulatory power over distributors of patented medicines.
Pursuant to subsection 96(4) of the Patent Act, the PMPRB issues a set of guidelines on matters including the price review process, the commencement of investigation, hearing recommendation and ordering of remedies. The guidelines provide rules of general application but are not binding on the PMPRB.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bereskin & Parr, PMPRB, federal drug price, Patent Act, GDP, medicine, clinical impact, regulation, generics, innovation, pharmaceutical industry